Replies to post #148032 on Biotech Values

[biomaven0]

>>i assume this bodes well for ponatinib

Yes, it shows the FDA can move very quickly indeed when the data is outstanding. Under 14 weeks from submission to approval

Of course Aria hasn't yet completed their application, so the FDA can't yet even formally accept it.

Peter